Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals in collaboration with the Skirball Foundation, will assess the effect of its drug candidate, Trimesta (oral estriol), on cognitive dysfunction seen in female multiple sclerosis (MS) patients during a study.
Subscribe to our email newsletter
The new double-blind, placebo-controlled, randomized Phase II clinical trial is expected to recruit 64 relapsing-remitting or secondary-progressive female MS patients aged between 18 and 50.
The primary endpoint of study includes better cognition scores in the Trimesta group compared to the placebo group based on paced auditory serial addition test (PASAT ) cognitive testing scores.
Study principal investigator Rhonda Voskuhl said at some point, 50-65% of MS patients will develop problems due to cognitive loss, yet there remains no treatment to target this disability.
"We are therefore thrilled to begin this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition and the ultimate goal is to address an unmet need for these patients," Voskuhl added.